Stay updated on Efprezimod Alfa as Immunomodulator in COVID-19 Clinical Trial
Sign up to get notified when there's something new on the Efprezimod Alfa as Immunomodulator in COVID-19 Clinical Trial page.

Latest updates to the Efprezimod Alfa as Immunomodulator in COVID-19 Clinical Trial page
- ChecktodayChange DetectedRevision tag updated from v3.5.4 to v3.5.5 on the page, indicating a small maintenance or content update to the study record. This change does not necessarily alter the study details or user-facing information.SummaryDifference0.0%

- Check7 days agoNo Change Detected
- Check14 days agoNo Change Detected
- Check21 days agoChange DetectedThe page now shows Revision: v3.5.4, replacing the previous v3.5.3. This reflects a minor site version update for the study record and does not alter the study details or related information.SummaryDifference0.0%

- Check43 days agoChange DetectedThe page footer/site release label has been updated from revision v3.5.2 to v3.5.3, reflecting a website software update rather than any change to the study record itself.SummaryDifference0.0%

- Check50 days agoChange DetectedAdded Revision: v3.5.2; Deleted Revision: v3.5.0.SummaryDifference0.0%

- Check79 days agoChange DetectedA new page revision v3.5.0 was added and the previous revision v3.4.3 was removed.SummaryDifference0.0%

- Check86 days agoChange DetectedRevision: v3.4.3 is now displayed, replacing the previous v3.4.2.SummaryDifference0.0%

Stay in the know with updates to Efprezimod Alfa as Immunomodulator in COVID-19 Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Efprezimod Alfa as Immunomodulator in COVID-19 Clinical Trial page.